Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

Sridevi Challa, W. Lee Kraus

Research output: Contribution to journalArticlepeer-review

Abstract

In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.

Original languageEnglish (US)
Pages (from-to)171-173
Number of pages3
JournalCell Chemical Biology
Volume29
Issue number2
DOIs
StatePublished - Feb 17 2022

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib'. Together they form a unique fingerprint.

Cite this